Zentalis prices 23M-share offering at $3.50, netting ~$75.1M

Zentalis Pharmaceuticals, Inc.

Offering of 23,000,000 shares at $3.50/share; underwriters have 30-day option for 3,450,000 additional shares.
Net proceeds estimated at $75.1M after underwriting discounts and offering expenses.
Closing expected August 17, 2026, subject to customary conditions.
Proceeds to fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic, pre-commercial activities, and general corporate purposes.
Underwriters: TD Securities, Guggenheim Securities, and Oppenheimer & Co. as representatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.